You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Pregnant, lactating women shouldn't be administered Covid vaccine now: Govt

The vaccine should be administered with caution in persons with a history of any bleeding or coagulation disorder (like clotting factor deficiency, coagulopathy or platelet disorder, it said

Topics
Pregnant woman | Coronavirus Vaccine | Health Ministry

Press Trust of India  |  New Delhi 

Coronavirus, vaccine, covid, drugs, clinical trials

Interchangeability of COVID-19 vaccines is not permitted and pregnant and lactating women should not be administered the shots as they have not been part of any anti-clinical trial so far, the said on Thursday.

In a letter to all states and Union territories, the ministry highlighted that under the emergency use authorisation, coronavirus vaccination is indicated only for 18 years and above. If required, COVID-19 vaccine and other vaccines should be separated by an interval of at least 14 days.

"Interchangeability of COVID-19 vaccines is not permitted. Second dose should also be of the same COVID-19 vaccine which was administered as the first dose," the letter written by Manohar Agnani, Additional Secretary, Union said.

The ministry has listed precautions and contraindications for COVID-19 vaccination along with a comparative factsheet for both the vaccines (Covishield and Covaxin) which contains information on vaccine platform, physical specifications, dosage, cold-chain storage requirements, contraindications and minor AEFIs (adverse event following immunization).

It said this information should be disseminated to programme managers across all levels and through them to cold-chain handlers and vaccinators for ready reference.

Listing the contraindications, the cautioned against administration of the vaccine in persons with a history of anaphylactic or allergic reaction to a previous dose of COVID-19 vaccine, and in those with immediate or delayed onset anaphylaxis or allergic reaction to vaccines or injectable therapies, pharmaceutical products, food items, among others.

According to the letter, in case of persons having active symptoms of SARS-CoV-2 infection, coronavirus infected patients who have been given anti-SARS-CoV-2 monoclonal antibodies or convalescent plasma and acutely unwell and hospitalised patients due to any illness, the COVID-19 vaccination is to be deferred for four to eight weeks after recovery.

"Pregnant and lactating women have not been a part of any COVID-19 vaccine clinical trial so far. Therefore, women who are pregnant or not sure of their pregnancy and lactating women should not receive COVID-19 vaccine at this time," the letter stated.

The vaccine should be administered with caution in persons with a history of any bleeding or coagulation disorder (like clotting factor deficiency, coagulopathy or platelet disorder, it said.

"Following conditions are not contraindicated for COVID-19 vaccines --persons with past history of SARS-CoV-2 infection and or RT-PCR positive illness, history of chronic diseases and morbidities and immuno-deficiency, HIV, patients on immune suppression due to any condition," the letter stated.

Prime Minister Narendra Modi will launch India's massive COVID-19 vaccination drive on January 16 via video conferencing, even as adequate doses of Bharat Biotech's 'Covaxin' and Serum Institute's 'Covishield' vaccines have been delivered across the country to all states and Union territories.

The letter also mentions mild AEFIs following vaccination for both the vaccines.

In case of Covishied, some mildAEFI may occur like injection site tenderness, injection site pain, headache, fatigue, myalgia, malaise, pyrexia, chills and arthralgia and nausea.

Some mild AEFIs in case of Covaxin include injection site pain, headache, fatigue, fever, body ache, abdominal pain, nausea and vomiting, dizziness-giddiness, tremor, sweating, cold, cough and injection site swelling.

Paracetamol may be used to provide symptomatic relief from post vaccination adverse reactions, the letter added.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, January 14 2021. 23:44 IST
RECOMMENDED FOR YOU